Arnedo, M; Taffé, P; Sahli, R; Furrer, H; Hirschel, B; Elzi, L; Weber, R; Vernazza, P; Bernasconi, E; Darioli, R; Bergmann, S; Beckmann, JS; Telenti, A; Tarr, PE; Swiss, HIV Cohort Study (2007). Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy. Pharmacogenetics and genomics, 17(9), pp. 755-64. London: Lippincott Williams & Wilkins 10.1097/FPC.0b013e32814db8b7
Full text not available from this repository. (Request a copy)BACKGROUND: HIV-1 infected individuals have an increased cardiovascular risk which is partially mediated by dyslipidemia. Single nucleotide polymorphisms in multiple genes involved in lipid transport and metabolism are presumed to modulate the risk of dyslipidemia in response to antiretroviral therapy. METHODS: The contribution to dyslipidemia of 20 selected single nucleotide polymorphisms of 13 genes reported in the literature to be associated with plasma lipid levels (ABCA1, ADRB2, APOA5, APOC3, APOE, CETP, LIPC, LIPG, LPL, MDR1, MTP, SCARB1, and TNF) was assessed by longitudinally modeling more than 4400 plasma lipid determinations in 438 antiretroviral therapy-treated participants during a median period of 4.8 years. An exploratory genetic score was tested that takes into account the cumulative contribution of multiple gene variants to plasma lipids. RESULTS: Variants of ABCA1, APOA5, APOC3, APOE, and CETP contributed to plasma triglyceride levels, particularly in the setting of ritonavir-containing antiretroviral therapy. Variants of APOA5 and CETP contributed to high-density lipoprotein-cholesterol levels. Variants of CETP and LIPG contributed to non-high-density lipoprotein-cholesterol levels, a finding not reported previously. Sustained hypertriglyceridemia and low high-density lipoprotein-cholesterol during the study period was significantly associated with the genetic score. CONCLUSIONS: Single nucleotide polymorphisms of ABCA1, APOA5, APOC3, APOE, and CETP contribute to plasma triglyceride and high-density lipoprotein-cholesterol levels during antiretroviral therapy exposure. Genetic profiling may contribute to the identification of patients at risk for antiretroviral therapy-related dyslipidemia.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Infectiology |
UniBE Contributor: |
Furrer, Hansjakob |
ISSN: |
1744-6872 |
ISBN: |
17700364 |
Publisher: |
Lippincott Williams & Wilkins |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 14:59 |
Last Modified: |
05 Dec 2022 14:18 |
Publisher DOI: |
10.1097/FPC.0b013e32814db8b7 |
PubMed ID: |
17700364 |
Web of Science ID: |
000249186900008 |
URI: |
https://boris.unibe.ch/id/eprint/25678 (FactScience: 60454) |
Actions (login required)
 |
Edit item |